Table 5 Results of publications of partial evaluations for liver metastases from colorectal cancer (lmCRC)

Fusco, 2017 [28]

(2016)

lmCRC

(First line treatment)^a

Y-90 TARE + FOLFOX

£ 209.44^b

221.83 $US PPP

Δ QoL utilities (EQ-5D-3 L):

-0.001 at 2 months (CI 95%: -0.05, 0.05), -0.03 at 12 months (-0.16, 0.09),

0.03 at 24 months, (-0.09, 0.16), and

-0.03 at 36 months (-0.20, 0.14).

FOLFOX

£ 158.85^b

168.25 $US PPP

Δ Cost at first year: £ 51.79^c

Δ Cost by 3 years: £ 56,38^c

54,85 $US PPP

59,72 $US PPP

Dhir, 2018 [29]

(2018)^c

lmCRC

(Second line treatment)^d

Y-90 TARE + MDR

$ 39,092 (n = 13; 2 days)

41,238 $US PPP

Median OS (since lmCRC diagnosis)

Y-90 TARE: 16.3 months (12.2–22.4)

HAI: 31.2 months (20.8–35.5)

HAI + MDR

$ 29,479 (n = 21; 9 days)

31,097 $US PPP

Δ Cost (median): $15,948

16,824 $US PPP